152 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements … , the Representatives shall have received the written opinion and negative assurance statement of Wilson Sonsini Goodrich & Rosati, P.C., counsel
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
We … financial data. Accordingly, Marcum LLP does not express an opinion or any other form of assurance with respect thereto. Additional information
424B5
7wzan
2 May 24
Prospectus supplement for primary offering
4:04pm
S-3ASR
6wix77yb6e 6s5
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-1.1
jn8wjdj329 h9etws
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
2l312e 7s1yk
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
qzya92u17 d7b
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
uzbrmdd
27 Sep 23
Prospectus supplement for primary offering
5:26pm